AR083991A1 - Derivados glicinicos de azabiciclo[2.2.2]octano, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades respiratorias broncoobstructivas o inflamatorias - Google Patents

Derivados glicinicos de azabiciclo[2.2.2]octano, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades respiratorias broncoobstructivas o inflamatorias

Info

Publication number
AR083991A1
AR083991A1 ARP110104393A ARP110104393A AR083991A1 AR 083991 A1 AR083991 A1 AR 083991A1 AR P110104393 A ARP110104393 A AR P110104393A AR P110104393 A ARP110104393 A AR P110104393A AR 083991 A1 AR083991 A1 AR 083991A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
heteroaryl
aryl
alkoxy
Prior art date
Application number
ARP110104393A
Other languages
English (en)
Inventor
Marco Farina
Gabriele Amari
Mauro Riccaboni
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of AR083991A1 publication Critical patent/AR083991A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado porque es de fórmula general (1) donde: R1 se selecciona entre el grupo que consiste en -H, alquilo C1-10 lineal o ramificado, alquenilo C2-6, arilo, cicloalquilo C3-8, heterocicloalquilo C5-10, arilalquilo C1-6 y heteroarilo, opcionalmente sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en átomos de halógeno, -OH, oxo (=O), -SH, -NO2, -N(R5)(R6), -CN, -CON(R5)2, -NHCO(R5), -COR5, -CO2R5, alquilsulfanilo C1-10, alquilsulfinilo C1-10, alquilsulfonilo C1-10, alquilo C1-10, alquilcarboxilo C1-10, alcoxi C1-10, arilo, ariloxi y heteroarilo; G se selecciona entre el grupo que consiste en -OC(O)-, -SO2- y -C(O)-; R2 se selecciona entre el grupo que consiste en -H, alquilo C1-10 y arilalquilo C1-6, opcionalmente sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en átomos de halógeno, -OH, oxo (=O), -SH, -NO2, -N(R5)2, -CN, -CON(R5)2, -NHCO(R5), -CO(R5), -CO2(R5), alquilsulfanilo C1-10, alquilsulfinilo C1-10, alquilsulfonilo C1-10, alquilo C1-10, alquilcarboxilo C1-10, alcoxi C1-10, arilo, ariloxi y heteroarilo; R3 se selecciona entre el grupo que consiste en -H, alquilo C1-10, arilo, cicloalquilo C3-8, heteroarilo, arilalquilo C1-6 y heteroarilalquilo C1-6, opcionalmente sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en átomos de halógeno, -OH, oxo (=O), -SH, -NO2, -N(R5)2, -CN, -CON(R5)2, -NHCO(R5), -CO(R5), -CO2(R5), alquilsulfanilo C1-10, alquilsulfinilo C1-10, alquilsulfonilo C1-10, alquilo C1-10, alquilcarboxilo C1-10, alcoxi C1-10, arilo, ariloxi, arilalquilenoxi C1-10 y heteroarilo; R6 se selecciona entre el grupo que consiste en los residuos del grupo de formulas (i), (ii) (iii) y (iv), donde m = 1, 2 ó 3; n = 1, 2 ó 3; A- es un anión fisiológicamente aceptable; R4 es un grupo de fórmula: ---(CH2)p---P---(CH2)q-W donde p es 0 o un entero entre 1 y 4; q es 0 o un entero entre 1 y 4; P se encuentra ausente o se selecciona entre el grupo que consiste en -O-, -S-, -SO-, -SO2-, -C(O)-, -N(R5)-, -CH=CH-, -N(R5)(SO2)-, -N(R5)(COO)-, -N(R5)(C(O))-, -S(O2)N(R5)-, -CO(O)N(R5)- y -C(O)N(R5)-; W se selecciona entre el grupo que consiste en H, alquilo C1-10 lineal o ramificado, alquenilo C2-6, arilo, cicloalquilo C3-8, heterocicloalquilo C5-10, arilalquilo C1-6 y heteroarilo, opcionalmente sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en átomos de halógeno, -OH, oxo (=O), -SH, -NO2, -N(R5)2, -CN, -CON(R5)2, -NH(COR5), -CO(R5), -CO2(R5), alquilsulfanilo C1-10, alquilsulfinilo C1-10, alquilsulfonilo C1-10, alquilo C1-10, alquilcarboxilo C1-10, alcoxi C1-10, arilo, ariloxi y heteroarilo; R5 y R6 se seleccionan independientemente entre el grupo que consiste en -H, alquilo C1-10, alcoxi C1-10, alquinilo C2-6, alquenilo C2-6, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-10, heteroarilo, alquil C1-10-heteroarilo y arilo opcionalmente sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en átomos de halógeno, -OH, oxo (=O), -SH, -NO2, -CN, -CONH2, alquilsulfanilo C1-10, alquilsulfinilo C1-10, alquilsulfonilo C1-10, alquilo C1-10, alquilcarboxilo C1-10, alcoxi C1-10, arilo, ariloxi y heteroarilo; y sales farmacéuticamente aceptables del mismo.
ARP110104393A 2010-11-26 2011-11-24 Derivados glicinicos de azabiciclo[2.2.2]octano, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades respiratorias broncoobstructivas o inflamatorias AR083991A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10192713 2010-11-26

Publications (1)

Publication Number Publication Date
AR083991A1 true AR083991A1 (es) 2013-04-10

Family

ID=43608596

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104393A AR083991A1 (es) 2010-11-26 2011-11-24 Derivados glicinicos de azabiciclo[2.2.2]octano, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades respiratorias broncoobstructivas o inflamatorias

Country Status (10)

Country Link
US (1) US8772314B2 (es)
EP (1) EP2643295B1 (es)
KR (1) KR20130141534A (es)
CN (1) CN103221390B (es)
AR (1) AR083991A1 (es)
BR (1) BR112013012160A2 (es)
CA (1) CA2820600A1 (es)
HK (1) HK1186176A1 (es)
RU (1) RU2585767C2 (es)
WO (1) WO2012069275A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140105746A (ko) 2011-12-30 2014-09-02 키에시 파르마슈티시 엣스. 피. 에이. 항무스카린제로서 1-아자헤테로시클릴아세트산의 퀴누클리딘 에스터, 이들의 제조 방법 및 이들의 의약 조성물
EP2928879B1 (en) * 2012-12-05 2018-02-28 Chiesi Farmaceutici S.p.A. Phenylethylpyridine derivatives as pde4-inhibitors and muscarinic receptor antagonists
ES2682105T3 (es) 2014-05-12 2018-09-18 Verona Pharma Plc Nuevo tratamiento

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021820A1 (fr) * 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive du carbamate et composition correspondante
HU229362B1 (en) * 1997-08-22 2013-11-28 Hoffmann La Roche N-alkanoylphenylalanine derivatives
WO2002051841A1 (en) * 2000-12-22 2002-07-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists
WO2003053966A2 (en) 2001-12-20 2003-07-03 Laboratorios S.A.L.V.A.T., S.A. 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists
EP1882691A1 (en) 2006-07-26 2008-01-30 CHIESI FARMACEUTICI S.p.A. Quinuclidine derivatives as M3 antagonists
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
EP2206712A1 (en) 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. "Alkaloid aminoester derivatives and medicinal composition thereof"
WO2011160919A1 (en) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal composition thereof
KR20130111968A (ko) 2010-06-22 2013-10-11 키에시 파르마슈티시 엣스. 피. 에이. 알칼로이드 아미노에스테르 유도체 및 이의 의약 조성물
KR20130087405A (ko) 2010-06-22 2013-08-06 키에시 파르마슈티시 엣스. 피. 에이. 알칼로이드 아미노에스테르 유도체 및 이의 의약 조성물

Also Published As

Publication number Publication date
RU2013123694A (ru) 2014-11-27
HK1186176A1 (en) 2014-03-07
US20120134934A1 (en) 2012-05-31
EP2643295B1 (en) 2016-04-13
CN103221390A (zh) 2013-07-24
BR112013012160A2 (pt) 2019-09-24
CA2820600A1 (en) 2012-05-31
WO2012069275A1 (en) 2012-05-31
CN103221390B (zh) 2015-06-03
KR20130141534A (ko) 2013-12-26
US8772314B2 (en) 2014-07-08
RU2585767C2 (ru) 2016-06-10
EP2643295A1 (en) 2013-10-02

Similar Documents

Publication Publication Date Title
AR059942A1 (es) Derivados de benzamidina y usos relacionados de los mismos
AR087311A1 (es) Quinolinas sustituidas y su uso como medicamentos
AR075789A1 (es) Derivados de bencimidazol, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la inhibicion de la prostaglandina microsomica e2 sintasa-1 (mpnges-1)
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
BR112015022174A8 (pt) compostos esteróides neuroativos, sua composição farmacêutica e seu uso
CY1116989T1 (el) C-28 αμινες c-3 τροποποιημενων παραγωγων βετουλινικου οξεος ως αναστολεις hiv ωριμανσης
SV2010003751A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
UA108221C2 (uk) Похідні тіофен-2-карбонової кислоти як інгібітори вірусів flaviviridae
MX2010005824A (es) Derivados de aminotiazol.
NO20084783L (no) Syntese av acylaminoalkenylenamider nyttige som substans P antagonister
BR112014000713A2 (pt) derivados de indol substituído como moduladores de gama secretase
MX2012004426A (es) Inhibidores macrociclicos de integrasa.
AR078507A1 (es) Compuestos lipidicos, composiciones farmaceuticas, usos y metodo de preparacion
CR20120295A (es) Triazolopiridinas
AR074341A1 (es) Derivados heterociclicos de isoindol, inhibidores de proteinasas bace, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de patologias relacionadas a deficiencias cognitivas, tales como alzheimer.
AR045407A1 (es) Compuesto de tiazolidin-4-ona, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
AR082443A1 (es) Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa
BR112012015967A2 (pt) uso de compostos de fórmula geral (i) e composição farmacêutica
BR112014007405A2 (pt) composto; forma farmacêutica; e hexasulfato de inositol
MX2010003224A (es) Derivados de biaril sulfonamida.
AR094975A1 (es) Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofílica
MX2010005714A (es) Compuestos de piridina.
PE20142366A1 (es) Compuestos triazolo como inhibidores de pde 10
BR112012011310A2 (pt) compostos derivados de 8-azabiciclo[3.2.1]octano-8-carboxamida, seu medicamento, seu agente terapêutico e seu uso
IT1393112B1 (it) Procedimento per la preparazione di derivati di prostaglandine

Legal Events

Date Code Title Description
FB Suspension of granting procedure